Essa Pharma assumed with an Outperform at Oppenheimer

Oppenheimer analyst Leland Gershell assumed coverage of Essa Pharma with an Outperform rating and $17 price target. There was no change to the firm’s estimates or price target, and Oppenheimer’s rating remains intact.